Efficacy of switching to infliximab in patients with Crohn's disease with loss of response to adalimumab.
BACKGROUND AND STUDY AIMS: Anti-TNF monoclonal antibodies are a cornerstone in the treatment of Crohn's disease. Prospective data on switching from the subcutaneous and human adalimumab (ADM) to the intravenous and chimeric infliximab (IFX) are scarce. PATIENTS AND METHODS: In this prospective, observational, multicentre cohort study we included 21 patients with loss of response to ADM despite at least 4 consecutive weekly injections. Clinical response (CDAI drop>/=70 points) and remission (CDAI</=150) were assessed after switching from ADM to IFX after 10 weeks, 6 and 12 months. Predict... Mehr ...
Verfasser: | |
---|---|
Dokumenttyp: | journal article |
Erscheinungsdatum: | 2018 |
Verlag/Hrsg.: |
Acta Medica Belgica
|
Schlagwörter: | Adalimumab/therapeutic use / Adult / Aged / Belgium / Crohn Disease/drug therapy / Female / Gastrointestinal Agents/therapeutic use / Humans / Infliximab/therapeutic use / Male / Middle Aged / Prospective Studies / Treatment Outcome / Crohn's disease / adalimumab / infliximab / switching / Human health sciences / Gastroenterology & hepatology / Sciences de la santé humaine / Gastroentérologie & hépatologie |
Sprache: | Englisch |
Permalink: | https://search.fid-benelux.de/Record/base-26976913 |
Datenquelle: | BASE; Originalkatalog |
Powered By: | BASE |
Link(s) : | https://orbi.uliege.be/handle/2268/229798 |